Genetics of schizophrenia: implications for treatment

References

• Gottesman I. Schizophrenia Genesis: The Origins of Iffickess. WH Freeman, NY, USA (1991).
   Google Scholar
• •Good introduction to schizophrenia.
   Google Scholar
• Moldin SO. The maddening hunt for madness genes. Nature Genetics 17, 127–129 (1997).
   PubMedGoogle Scholar
• Levinson DF, Holmans P, Straub RE et al Multicenter linkage study of schizophrenia candidate regions on chromosomes 5q, 6q, 10p and 13q: schizophrenia linkage collaborative group III. Am. J: Hum. Genet. 67(3), 652–663 (2000).
   Google Scholar
• Levinson DF, Levinson MD, Segurado R, Lewis CM. Genome scan meta-analysis of schizophrenia and bipolar disorder, part I: methods and power analysis. Am. J: Hum. Genet. 73(1), 17–33 (2003).
   Google Scholar
• Nimgaonkar V. In defense of genetic association studies. Mal Psychiatry2, 275–277 (1997).
   PubMedGoogle Scholar
• Baron M. Genetics of schizophrenia in the new millenium: progress and pitfalls. Am J: Hum. Genet. 68(2), 299–312 (2001).
   Google Scholar
• O' Donovan MC, Owen MJ. Candidate Gene-association studies of schizophrenia. Am. Hum. Genet. 65(3), 587–592 (1999).
   Google Scholar
• •Cogent defense of candidate gene studies.
   Google Scholar
• Crowe RR. Candidate genes in psychiatry: an epidemiological perspective. Am. J: Hum. Genet. (2), 74–77 (1993).
   Google Scholar
• Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361(9355), 417–419 (2003).
   PubMed Web of Science ®Google Scholar
• •Update on candidate gene studies in schizophrenia, with a hypothesis explaining the functional implications.
   Google Scholar
• Chowdari KV, Mimics K, Semwal P et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum. Mal Genet. 11(12), 1373–1380 (2002).
   Google Scholar
• Williams NM, Preece A, Spurlock G et al. Support for RGS4 as a susceptibility gene for schizophrenia. Biol. PTchiatry55 (2), 192–195 (2004).
   Google Scholar
• Morris DW, Rodgers A, McGhee IKA et al Confirming RGS4 as a susceptibility gene for schizophrenia. Am. J: Hum. Genet. 125B(1), 50–53 (2004).
   Google Scholar
• Chumakov I, Blumenfeld M, Guerassimenko 0 et al Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl Acad. Li. USA 99(21), 13675–13680 (2002).
   Google Scholar
• Stefansson H, Sigurdsson E, Steinthorsdottir V et al Neuregulin 1 and susceptibility to schizophrenia. Am. J: Hum. Genet. 71(4), 877–892 (2002).
   Google Scholar
• Stefansson H, Sarginson J, Kong A et al Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am. J: Hum. Genet. 72 (1), 83–87 (2003).
   Google Scholar
• Williams NM, Preece A, Spurlock G et al. Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mal Psych. 8(5), 485–487 (2003).
   Google Scholar
• Straub RE, MacLean CJ, Ma Y et al. Genome-wide scans of three independent sets of 90 Irish multiplex schizophrenia families and follow-up of selected regions in all families provides evidence for multiple susceptibility genes. Mal Psych. 7(6), 542–559 (2002).
   Google Scholar
• Schwab SG, Knapp M, Mondabon S et al Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am.j Hum. Genet. 72 (1), 185–190 (2003).
   Google Scholar
• Morris DW, McGhee IKA, Schwaiger S et al No evidence for association of the dysbindin gene with schizophrenia in an Irish population-based study. Schizophr Res. 60(2-3), 167–172(2003).
   Google Scholar
• van den Oord EJ, Sullivan PF, Jiang Y et al Identification of a high-risk haplotype for the dystrobrevin binding protein 1 (DTNBP1) gene in the Irish study of high-density schizophrenia families. Mal Psych. 8(5), 499–510 (2003).
   Google Scholar
• Wright AF, Carothers AD, Pirastu M. Population choice in mapping genes for complex diseases. Nature Genetics 23(4), 397–404 (1999).
   PubMedGoogle Scholar
• Risch NJ. Searching for genetic determinants in the new millennium.Nature 405 (6788), 847–856, (2000).
   PubMed Web of Science ®Google Scholar
• Altmuller J, Palmer LJ, Fischer G, Scherb H, Yjst M. Genomewide scans of complex human diseases, True linkage is hard to find. Am. .1. Hum. Genet. (2004) (In Press).
   Google Scholar
• Sklar P, Schwab SG, Williams NM, Daly M et al Association analysis of NOTCH4 loci in schizophrenia using family and population-based controls. Nature Genetics 28(2), 126–128 (2001).
   Google Scholar
• Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286,487–491 (1999).
   PubMed Web of Science ®Google Scholar
• •Basic review of pharrnacogenomics.
   Google Scholar
• Arranz M, Collier D, Sodhi M et al Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346(8970), 281–282 (1995).
   Google Scholar
• Arranz MJ, Collier DA, Munro J et al Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci. Lett. 217(2–3), 177–178 (1996).
   Google Scholar
• Scharfetter J. Dopamine receptor polymorphisms and drug response in schizophrenia. Pharmacogenomics 2 (3), 251–261 (2001).
   PubMedGoogle Scholar
• Arranz MJ, Mancama DT, Kerwin RVV. Pharmacogenetic and pharmacogenomic research in psychiatry: current advances and clinical applications. CUI7: Pharmacogenomics 1 (3), 151–158 (2003) .
   Google Scholar
• •A clear and comprehensive review of pharrnacogenomics in relation to psychiatry.
   Google Scholar
• Potkin SG, Basile VS, Jin Y et al. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mal fiychiatry8(1), 109–113 (2003).
   Google Scholar
• Malhotra AK, Buchanan RVV, Kim S et al Allelic variation in the promoter region of the dopamine D2 receptor gene and clozapine response. Schizophr Res. 36 (1–3), 92–93 (1999).
   Google Scholar
• Scharfetter J, Chaudhry HR, Honk K et al Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Palcastani patients. Eur. Neumpsychophatmacol 10(1), 17–20 (1999).
   Google Scholar
• Lin CH, Tsai SJ, Yu YVV et al No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neummport 10(1), 57–60 (1999).
   Google Scholar
• Masellis M, Basile V, Meltzer HY et al Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neumpsychophatmacology19(2), 123–132 (1998).
   Google Scholar
• Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MET, Chang WH. Association of risperidone treatment response with a polymorphism in the 5-HT2A receptor gene. Am.j Psychiatry159(9), 1593–1595 (2002).
   Google Scholar
• Sodhi MS, Arranz MJ, Curtis D et al Association between clozapine response and allelic variation in the 5-HT2c receptor gene. Neuroreport 7(1), 169–172 (1995).
   Google Scholar
• Schumacher J, Schulze TG, Wienker TF, Rietschel M, Nothen MM. Pharmacogenetics of the clozapine response. Lancet 356 (9228), 506–507 (2000).
   PubMed Web of Science ®Google Scholar
• Yu YVV, Tsai SJ, Lin CH, Hsu CP, Yang KH, Hong CJ. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuromport 10(6), 1231–1233 (1999).
   Google Scholar
• Tsai SJ, Wang YC, Yu Younger WY, Lin CH, Yang KH, Hong CJ. Association analysis of polymorphism in the promoter region of the a-2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr Res. 49(1–2), 53–58 (2001).
   Google Scholar
• Bolonna AA, Arranz MJ, Munro J et al No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neumsci. Lett. 280(1), 65–68 (2000).
   PubMedGoogle Scholar
• Mancama D, Arranz MJ, Munro J et al. Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neurosci. Lett. 333(3), 207–211 (2002).
   Google Scholar
• Arranz MJ, Lin MW Powell J, Kerwin R, Collier D. 5-HT2A receptor T102C polymorphism and schizophrenia. Lancet 347(9018), 1831–1832 (1996).
   Google Scholar
• Malhotra AK, Kennedy JL, Collier DA, Rietschel M. Pharmacogenetics in psychiatry satellite meeting at the American College of Neuropsychopharmacology 2000. Neuropsychopharmacology26(1), 123–127 (2002).
   Google Scholar
• Rietschel M, Kennedy JL, Macciardi F, Meltzer HY. Application of pharmacogenetics to psychotic disorders, the first consensus conference. The Consensus Group for Outcome Measures in Psychoses for Pharmacological Studies. Schizophr Res. 37(2), 191–196 (1999).
   PubMedGoogle Scholar
• Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum. Mal Genet. 11(20), 2517–2530 (2002).
   PubMed Web of Science ®Google Scholar